Johnson & Johnson Vision is broadening the reach of its contact lenses specially designed to help fight nearsightedness, led by a new FDA green light.

Galecto has linked its myelofibrosis candidate GB2064 to reduced collagen fibrosis in a small clinical trial, offering early validation of the ability of the LOXL2 inhibitor to act on a variable that affects outcomes.

Axcella Therapeutics has presented a glimpse at data from its ongoing, blinded phase 2b nonalcoholic steatohepatitis (NASH) trial, linking the high dose of its orally active mixture of amino acids to improved liver stiffness at week 24.

Every year in the U.S., doctors perform more than 1 million endoscopic hemostasis procedures to treat gastrointestinal bleeding, the majority of which are upper GI bleeds. One popular treatment method relies on catheter-based hemostatic sprays, which cover a bleeding site in a powder coating to stanch the bleed and speed up the clotting process but which can quickly become clogged and may be difficult to navigate through the GI tract.

TCR2 Therapeutics has reported updated data from a phase 1 clinical trial of gavo-cel, linking the T-cell therapy to a 22% response rate in solid tumor patients who received the treatment after chemotherapy depletion.

More than 12 hours since Eisai and Biogen announced a phase 3 victory for their Alzheimer’s drug lecanemab, much of the biotech world has become completely giddy.

BioIVT has bought Fidelis Research for an undisclosed price, marking the second acquisition for the biological specimens and services firm this month.

Eisai’s phase 3 clinical trial of Biogen-partnered Alzheimer’s disease candidate lecanemab has hit its primary and key secondary endpoints. The result, which analysts at Evercore ISI called a “major surprise,” gives a big boost to the partners as they head toward an accelerated approval decision in January.

Avidity Biosciences’ lead program has hit choppy waters. The FDA has put the phase 1/2 MARINA clinical trial of RNA therapeutic AOC 1001 on partial hold in response to a serious adverse event in one patient.

Philips’ respiratory device-focused Respironics business has been in the hot seat for well over a year now, ever since it identified a potentially fatal safety issue with the sound-muffling foam of around 5.5 million of its CPAP and BiPAP machines and other ventilators.